Hepatocellular carcinoma screening and diagnosis

Morris Sherman, Massimo Colombo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

All the major liver disease societies have recommended screening for hepatocellular carcinoma (HCC). The target population for HCC screening has been defined by cost-efficacy analyses and by risk scores. Risk scores have been developed for patients with hepatitis B, regardless of the presence of cirrhosis, and for other patients with cirrhosis. Screening is with ultrasound; however, in Asia biomarkers are also used. The additional value of biomarkers has not been demonstrated. The ideal screening interval is 6 months; in Japan shorter intervals are used. Screening detects small lesions that require confirmation of HCC. There are radiological criteria that help determine whether a biopsy is necessary. Special stains can determine whether a lesion that closely resembles normal or dysplastic tissue is HCC. All these tools should be used in the management of patients undergoing HCC screening.

Original languageEnglish
Pages (from-to)389-397
Number of pages9
JournalSeminars in Liver Disease
Volume34
Issue number4
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Biomarkers
Health Services Needs and Demand
Hepatitis B
Liver Diseases
Japan
Coloring Agents
Biopsy
Costs and Cost Analysis

Keywords

  • alpha fetoprotein
  • cost-efficacy analysis
  • hepatocellular carcinoma
  • risk scores

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Hepatocellular carcinoma screening and diagnosis. / Sherman, Morris; Colombo, Massimo.

In: Seminars in Liver Disease, Vol. 34, No. 4, 01.11.2014, p. 389-397.

Research output: Contribution to journalArticle

Sherman, Morris ; Colombo, Massimo. / Hepatocellular carcinoma screening and diagnosis. In: Seminars in Liver Disease. 2014 ; Vol. 34, No. 4. pp. 389-397.
@article{c9aa4fafce7349c9aa503e3b4923854b,
title = "Hepatocellular carcinoma screening and diagnosis",
abstract = "All the major liver disease societies have recommended screening for hepatocellular carcinoma (HCC). The target population for HCC screening has been defined by cost-efficacy analyses and by risk scores. Risk scores have been developed for patients with hepatitis B, regardless of the presence of cirrhosis, and for other patients with cirrhosis. Screening is with ultrasound; however, in Asia biomarkers are also used. The additional value of biomarkers has not been demonstrated. The ideal screening interval is 6 months; in Japan shorter intervals are used. Screening detects small lesions that require confirmation of HCC. There are radiological criteria that help determine whether a biopsy is necessary. Special stains can determine whether a lesion that closely resembles normal or dysplastic tissue is HCC. All these tools should be used in the management of patients undergoing HCC screening.",
keywords = "alpha fetoprotein, cost-efficacy analysis, hepatocellular carcinoma, risk scores",
author = "Morris Sherman and Massimo Colombo",
year = "2014",
month = "11",
day = "1",
doi = "10.1055/s-0034-1394139",
language = "English",
volume = "34",
pages = "389--397",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers, Inc.",
number = "4",

}

TY - JOUR

T1 - Hepatocellular carcinoma screening and diagnosis

AU - Sherman, Morris

AU - Colombo, Massimo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - All the major liver disease societies have recommended screening for hepatocellular carcinoma (HCC). The target population for HCC screening has been defined by cost-efficacy analyses and by risk scores. Risk scores have been developed for patients with hepatitis B, regardless of the presence of cirrhosis, and for other patients with cirrhosis. Screening is with ultrasound; however, in Asia biomarkers are also used. The additional value of biomarkers has not been demonstrated. The ideal screening interval is 6 months; in Japan shorter intervals are used. Screening detects small lesions that require confirmation of HCC. There are radiological criteria that help determine whether a biopsy is necessary. Special stains can determine whether a lesion that closely resembles normal or dysplastic tissue is HCC. All these tools should be used in the management of patients undergoing HCC screening.

AB - All the major liver disease societies have recommended screening for hepatocellular carcinoma (HCC). The target population for HCC screening has been defined by cost-efficacy analyses and by risk scores. Risk scores have been developed for patients with hepatitis B, regardless of the presence of cirrhosis, and for other patients with cirrhosis. Screening is with ultrasound; however, in Asia biomarkers are also used. The additional value of biomarkers has not been demonstrated. The ideal screening interval is 6 months; in Japan shorter intervals are used. Screening detects small lesions that require confirmation of HCC. There are radiological criteria that help determine whether a biopsy is necessary. Special stains can determine whether a lesion that closely resembles normal or dysplastic tissue is HCC. All these tools should be used in the management of patients undergoing HCC screening.

KW - alpha fetoprotein

KW - cost-efficacy analysis

KW - hepatocellular carcinoma

KW - risk scores

UR - http://www.scopus.com/inward/record.url?scp=84926144379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926144379&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1394139

DO - 10.1055/s-0034-1394139

M3 - Article

C2 - 25369301

AN - SCOPUS:84926144379

VL - 34

SP - 389

EP - 397

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -